Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Dec 6 (Reuters) - Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with ...

(NewsNation) — Doctors used personal gene therapy to treat an infant with a deadly genetic disease in a medical first. KJ Muldoon was born in August of 2024, and DNA sequencing revealed he had ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A group of scientists successfully made a bespoke gene ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

A rare disease mom and scientist shares on the "First Opinion Podcast" how she serves as a translator between her two ...

Going from the laboratory to an approved therapy in 11 years is no mean feat. That is the story of the world’s first approved CRISPR–Cas9 therapy, greenlit by the US Food and Drug Administration in ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...